# Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

> **NCT05308966** · — · COMPLETED · sponsor: **Groupe Francais De Pneumo-Cancerologie** · enrollment: 204 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma
- Unresectable Malignant Neoplasm

## Interventions

- **OTHER:** Data collection

## Key facts

- **NCT ID:** NCT05308966
- **Lead sponsor:** Groupe Francais De Pneumo-Cancerologie
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-03
- **Primary completion:** 2025-08-27
- **Final completion:** 2025-08-27
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05308966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05308966, "Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05308966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*